Camille Verry1,2,3, Sandrine Dufort4,5, Emmanuel Luc Barbier2,3, Olivier Montigon2,3, Michel Peoc'h6, Philippe Chartier1, François Lux7, Jacques Balosso1, Olivier Tillement7, Lucie Sancey7, Géraldine Le Duc8,5. 1. Department of Radiotherapy, Grenoble Alpes University Hospital, BP217, F38043 Grenoble, Cedex 9, France. 2. Grenoble Institute of Neurosciences, Grenoble Alpes University, F38000 Grenoble, France. 3. INSERM U1216, F38000 Grenoble, France. 4. Nano-H SAS, F38070 Saint-Quentin-Fallavier, France. 5. Present affiliation: NH TherAguix, 43 boulevard du 11 novembre 1918, F69100 Villeurbanne, France. 6. Department of Pathology, Saint-Etienne University Hospital, F42055 Saint-Etienne, Cedex 2, France. 7. Institute Light & Mater, UMR5306, Lyon1 University-CNRS, Lyon University, F69622 Villeurbanne, France. 8. Biomedical Beamline, European Synchrotron Radiation Facility, CS40220, F38043 Grenoble, Cedex 9, France.
Abstract
AIM: This study reports the use of gadolinium-based AGuIX nanoparticles (NPs) as a theranostic tool for both image-guided radiation therapy and radiosensitization of brain tumors. MATERIALS & METHODS: Pharmacokinetics and regulatory toxicology investigations were performed on rodents. The AGuIX NPs' tumor accumulation was studied by MRI before 6-MV irradiation. RESULTS: AGuIX NPs exhibited a great safety profile. A single intravenous administration enabled the tumor delineation by MRI with a T1 tumor contrast enhancement up to 24 h, and the tumor volume reduction when combined with a clinical 6-MV radiotherapy. CONCLUSION: This study demonstrates the efficacy and the potential of AGuIX NPs for image-guided radiation therapy, promising properties that will be assessed in the upcoming Phase I clinical trial.
AIM: This study reports the use of gadolinium-based AGuIX nanoparticles (NPs) as a theranostic tool for both image-guided radiation therapy and radiosensitization of brain tumors. MATERIALS & METHODS: Pharmacokinetics and regulatory toxicology investigations were performed on rodents. The AGuIX NPs' tumor accumulation was studied by MRI before 6-MV irradiation. RESULTS:AGuIX NPs exhibited a great safety profile. A single intravenous administration enabled the tumor delineation by MRI with a T1 tumor contrast enhancement up to 24 h, and the tumor volume reduction when combined with a clinical 6-MV radiotherapy. CONCLUSION: This study demonstrates the efficacy and the potential of AGuIX NPs for image-guided radiation therapy, promising properties that will be assessed in the upcoming Phase I clinical trial.